Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00007020 · ClinicalTrials.gov registry record · Phase 3
Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
A Phase 3 study of Adrenoleukodystrophy and Cholestasis, sponsored by Mirum Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 85
- Enrollment target
- 1
- Study location
NCT00007020: Completed Phase 3 study of Adrenoleukodystrophy and Cholestasis, sponsored by Mirum Pharmaceuticals.
NCT00007020 is a Phase 3 study of Adrenoleukodystrophy and Cholestasis that has completed, run by Mirum Pharmaceuticals. The registered enrollment target is 85 participants, below the 2,207-participant average among 6 other Adrenoleukodystrophy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00007020, a Phase 3 study of Adrenoleukodystrophy and Cholestasis, has completed, sponsored by Mirum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 85 participants
- Enrollment target
- 1
- Study location
Study Summary
OBJECTIVES: I. To Evaluate the therapeutic efficacy of cholic acid during provision of compassionate treatment to patients with identified inborn errors of bile acid synthesis and metabolism II. To assess the safety and tolerability of cholic acid
Primary Outcome
Patients with excretion of atypical bile acids in urine by category, from worst status before treatment (baseline, BL) to best status on treatment (OT)
Conditions Studied
Interventions
- DRUG Cholic Acids
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 1992-01 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
What the finished NCT00007020 record still lists
NCT00007020 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 2,207-participant average among 6 other Adrenoleukodystrophy trials with a reported enrollment target (96% lower).
The record links to 5 conditions, with Adrenoleukodystrophy appearing as the primary indexed condition, and to 1 intervention - of which Cholic Acids is the first listed.
NCT00007020 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00007020 about?
NCT00007020 is a clinical study titled "Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid". OBJECTIVES: I. To Evaluate the therapeutic efficacy of cholic acid during provision of compassionate treatment to patients with identified inborn errors of bile acid synthesis and metabolism II. To assess the safety and tolerability of cholic acid
What is the current status of trial NCT00007020?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 85 participants. The study started on 1992-01. Estimated completion is 2009-12.
What conditions does trial NCT00007020 study?
This clinical trial studies the following conditions: Adrenoleukodystrophy, Cholestasis, Infantile Refsum's Disease, Zellweger Syndrome, Peroxisomal Disorders.
What interventions are being tested in trial NCT00007020?
The interventions under investigation include: Cholic Acids (DRUG).
Who is sponsoring clinical trial NCT00007020?
This trial is sponsored by Mirum Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00007020 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adrenoleukodystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adrenoleukodystrophy National Registry Study
RECRUITING
-
The Myelin Disorders Biorepository Project
RECRUITING
-
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
RECRUITING · Phase 1
-
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
ACTIVE NOT RECRUITING · Phase 4
-
Human Placental-Derived Stem Cell Transplantation
COMPLETED · Phase 1
-
Stem Cell Transplant for Inborn Errors of Metabolism
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia